Why the coronavirus is keeping biotech up at night
As China imposes sweeping restrictions to contain the coronavirus outbreak, a biotech industry increasingly dependent on outsourced work is worried about costly delays.
As STAT’s Kate Sheridan reports, biotech startups with vendors in China are concerned that the country’s crackdown on travel might suspend scientific work and delay their progress in drug development. So far, the effects have been minor, executives said, but the prospect of a months-long pause has led some biotech leaders to tap Western vendors just in case.
“We’d rather spend more money and have an overabundance of resources in the short run if, in fact, China comes back online in a few weeks or a month, instead of being completely out of the game for an extended period of time,” one biotech executive said.
Read more.
As STAT’s Kate Sheridan reports, biotech startups with vendors in China are concerned that the country’s crackdown on travel might suspend scientific work and delay their progress in drug development. So far, the effects have been minor, executives said, but the prospect of a months-long pause has led some biotech leaders to tap Western vendors just in case.
“We’d rather spend more money and have an overabundance of resources in the short run if, in fact, China comes back online in a few weeks or a month, instead of being completely out of the game for an extended period of time,” one biotech executive said.
Read more.
.png)
No hay comentarios:
Publicar un comentario